In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences.
The synthetic retinoid fenretinide (4-HPR; N-[4-hydroxyphenyl] all-trans-retinamide) interacts with plasma apo-retinol-binding protein (RBP) to form a tight complex (K'd approximately 0.2 microM) which does not exhibit binding affinity to transthyretin (TTR). Therefore, a substantial modification of the retinol hydroxyl group does not appear to affect the interaction with RBP but does drastically interfere with the protein-protein recognition. The remarkable early reduction in plasma retinol level induced by fenretinide administration may be associated with the high binding affinity of this retinoid to RBP and to its interference with the RBP-TTR complex formation.
Berni
R
R
Istituto di Scienze Biochimiche, Università di Parma, Italy.
Formelli
F
F
D000818:Animals; D002846:Chromatography, Affinity; D005260:Female; D017313:Fenretinide; D051381:Rats; D011919:Rats, Inbred Strains; D012177:Retinol-Binding Proteins / Q000378:metabolism*; D054839:Retinol-Binding Proteins, Plasma; D013379:Substrate Specificity; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000378:metabolism
D012177:Retinol-Binding Proteins; D054839:Retinol-Binding Proteins, Plasma; D017313:Fenretinide; D014212:Tretinoin